Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerhard Siemeister

Showing results (11-20 of 33) with videos related to

Pageof 4
Sort By:
Bioorganic & Medicinal Chemistry Letters|November 28, 2015
Optimization of allosteric MEK inhibitors. Part 2: Taming the sulfamide group balances compound distribution propertiesIngo V Hartung, Stefanie Hammer, Marion Hitchcock, et al.
Acta Crystallographica. Section D, Structural Biology|November 17, 2025
Polo-like kinase 1-inhibitor co-complex structures via the surface-entropy reduction approach and a DARPin-assisted approachUwe Eberspaecher, Arndt A Schmitz, Gerhard Siemeister, et al.
Chemmedchem|November 7, 2015
Modular Assembly of Allosteric MEK Inhibitor Structural Elements Unravels Potency and Feedback-Modulation HandlesIngo V Hartung, Florian Pühler, Roland Neuhaus, et al.
Bioorganic & Medicinal Chemistry Letters|March 12, 2013
Optimization of allosteric MEK inhibitors. Part 1: Venturing into underexplored SAR territoriesIngo V Hartung, Marion Hitchcock, Florian Pühler, et al.
Chemmedchem|May 15, 2013
The lab oddity prevails: discovery of pan-CDK inhibitor (R)-S-cyclopropyl-S-(4-{[4-{[(1R,2R)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide (BAY 1000394) for the treatment of cancerUlrich Lücking, Rolf Jautelat, Martin Krüger, et al.
Molecular Biology of the Cell|August 3, 2007
Use of the novel Plk1 inhibitor ZK-thiazolidinone to elucidate functions of Plk1 in early and late stages of mitosisAnna Santamaria, Rüdiger Neef, Uwe Eberspächer, et al.
Elife|February 18, 2016
Probing the catalytic functions of Bub1 kinase using the small molecule inhibitors BAY-320 and BAY-524Anna P Baron, Conrad von Schubert, Fabien Cubizolles, et al.
Frontiers in Oncology|June 1, 2012
Evaluation of activity and combination strategies with the microtubule-targeting drug sagopilone in breast cancer cell linesJulia Eschenbrenner, Sebastian Winsel, Stefanie Hammer, et al.
International Journal of Molecular Sciences|June 2, 2021
Additive Benefits of Radium-223 Dichloride and Bortezomib Combination in a Systemic Multiple Myeloma Mouse ModelMari I Suominen, Jenni Mäki-Jouppila, Anna Huhtinen, et al.
Signal Transduction and Targeted Therapy|April 19, 2018
Pan-CDK inhibition augments cisplatin lethality in nasopharyngeal carcinoma cell lines and xenograft modelsNicholas L Syn, Pei Li Lim, Li Ren Kong, et al.
Pageof 4

Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
Bioorganic & Medicinal Chemistry Letters|November 28, 2015
Optimization of allosteric MEK inhibitors. Part 2: Taming the sulfamide group balances compound distribution propertiesIngo V Hartung, Stefanie Hammer, Marion Hitchcock, et al.
Acta Crystallographica. Section D, Structural Biology|November 17, 2025
Polo-like kinase 1-inhibitor co-complex structures via the surface-entropy reduction approach and a DARPin-assisted approachUwe Eberspaecher, Arndt A Schmitz, Gerhard Siemeister, et al.
Chemmedchem|November 7, 2015
Modular Assembly of Allosteric MEK Inhibitor Structural Elements Unravels Potency and Feedback-Modulation HandlesIngo V Hartung, Florian Pühler, Roland Neuhaus, et al.
Bioorganic & Medicinal Chemistry Letters|March 12, 2013
Optimization of allosteric MEK inhibitors. Part 1: Venturing into underexplored SAR territoriesIngo V Hartung, Marion Hitchcock, Florian Pühler, et al.
Chemmedchem|May 15, 2013
The lab oddity prevails: discovery of pan-CDK inhibitor (R)-S-cyclopropyl-S-(4-{[4-{[(1R,2R)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide (BAY 1000394) for the treatment of cancerUlrich Lücking, Rolf Jautelat, Martin Krüger, et al.
Molecular Biology of the Cell|August 3, 2007
Use of the novel Plk1 inhibitor ZK-thiazolidinone to elucidate functions of Plk1 in early and late stages of mitosisAnna Santamaria, Rüdiger Neef, Uwe Eberspächer, et al.
Elife|February 18, 2016
Probing the catalytic functions of Bub1 kinase using the small molecule inhibitors BAY-320 and BAY-524Anna P Baron, Conrad von Schubert, Fabien Cubizolles, et al.
Frontiers in Oncology|June 1, 2012
Evaluation of activity and combination strategies with the microtubule-targeting drug sagopilone in breast cancer cell linesJulia Eschenbrenner, Sebastian Winsel, Stefanie Hammer, et al.
International Journal of Molecular Sciences|June 2, 2021
Additive Benefits of Radium-223 Dichloride and Bortezomib Combination in a Systemic Multiple Myeloma Mouse ModelMari I Suominen, Jenni Mäki-Jouppila, Anna Huhtinen, et al.
Signal Transduction and Targeted Therapy|April 19, 2018
Pan-CDK inhibition augments cisplatin lethality in nasopharyngeal carcinoma cell lines and xenograft modelsNicholas L Syn, Pei Li Lim, Li Ren Kong, et al.
Pageof 4